Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02145676 · ClinicalTrials.gov registry record · Phase 3
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
A Phase 3 study, sponsored by Allergan.
- Terminated
- Registry status
- Phase 3
- Development phase
- 53
- Enrollment target
NCT02145676 is a Phase 3 study that was terminated before completion, run by Allergan. The registered enrollment target is 53 participants.
The verdict
NCT02145676, a Phase 3 study, was terminated before completion, sponsored by Allergan.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 53 participants
- Enrollment target
Study Summary
This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
Interventions
- BIOLOGICAL onabotulinumtoxinA
- DRUG placebo (normal saline)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 53 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02145676
The ClinicalTrials.gov registry entry for NCT02145676 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allergan, which has 314 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which onabotulinumtoxinA is the first listed.
NCT02145676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02145676 about?
NCT02145676 is a clinical study titled "OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity". This is a safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.
What is the current status of trial NCT02145676?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 53 participants. The study started on 2014-05. Estimated completion is 2015-12.
What interventions are being tested in trial NCT02145676?
The interventions under investigation include: onabotulinumtoxinA (BIOLOGICAL), placebo (normal saline) (DRUG).
Who is sponsoring clinical trial NCT02145676?
This trial is sponsored by Allergan, which has 314 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.